UNSPSC 51291706: Flerobuterol

This classification denotes a beta-adrenergic agonist and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F05RR5M463. European Medicines Agency schedules Flerobuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07638MIG. Flerobuterol generally arises in the molecular formula C12H18FNO.

UNSPSC 51291706 Flerobuterol, a Commodity code, does not align with the recent state and local procurement activity posted under it. The three most recent opportunities—a Seminole County naloxone and drug deactivation systems buy, a Texas HHS direct-to-manufacturer prescription program RFI, and a Minnesota multistate cooperative purchasing RFP for generic pharmaceuticals and OTC products—address naloxone distribution, pharmacy benefit program structure, and multi-source generic drug sourcing respectively. None target flerobuterol specifically or pharmaceutical respiratory bronchodilators as a product category. The code shows little relevant recent activity in the state and local market; the opportunities logged under it appear to reflect broader pharmaceutical procurement and drug safety initiatives rather than the bronchodilator product the code nominally describes.

Seminole County, Florida issued the most recent opportunity with a concrete procurement need: IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023 (note: the source date is inconsistent), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term with optional one-year renewal. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor intelligence on direct-to-manufacturer prescription contracting, a market-research mechanism rather than a formal procurement. Minnesota's MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers serving state and local facilities across Minnesota and Oregon. The code sees activity across Florida, Texas, and Minnesota, but none of these solicitations targets flerobuterol or respiratory therapeutics as a primary procurement driver.